Clinical Trial Update: Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing mycophenolate mofetil for systemic sclerosis-related early interstitial lung disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease
• Scleroderma
• Systemic Sclerosis

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)

Snippet

Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh | Conditions: Systemic Sclerosis, Scleroderma | Phase 3 | Status: COMPLETED